• Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24nd Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona.

    These data will highlight exciting findings that have emerged over the past year, including:

    • Updated clinical results for ONC201 in pediatric and adult H3 K27M-mutant gliomas
    • Extension of ONC201 activity to other brain tumors
    • Synergy antitumor activity of ONC201 in combination with other treatments
    • Activity of ONC206 in medulloblastoma
    • IND-enabling studies with ONC206
    • Distinctions in the activity of ONC201 and ONC206
    • Inhibition of mitochondrial function by ONC201
    • The capability of the imipridone family to bind to distinct molecular targets

    Oncoceutics and academic investigators will present a range of results with imipridones that will include mechanistic and efficacy findings from preclinical models that detail their unique therapeutic potential in neuro-oncology. In addition, updated safety, pharmacokinetic, pharmacodynamic, and efficacy results from clinical trials with ONC201 in high-grade glioma patients will be reported. These results are largely derived from the ongoing clinical program that is dedicated to exploring ONC201 a molecularly-defined patient population (H3 K27M-mutant glioma). The rationale for the upcoming first-in-human clinical trial of ONC206 in adult recurrent CNS tumors will also be highlighted.

    Summaries and presentation information are provided below:

    Date/Time Location Abstract Title Presenter

    Wednesday 11/20
    9:40 – 9:50 PM JW Marriott Selective targeting of dopamine receptor dysregulation in high grade gliomas with ONC201 Varun Prabhu, PhD, Oncoceutics

    Thursday 11/21
    5:00 – 7:00 PM Investigator Meeting

    Friday 11/22
    7:30 – 9:30 PM Ballroom Lawn Imipridone Structure Activity Relationship Uncovers ONC206 as the Next Bitopic DRD2 Antagonist for Oncology with Differentiated Receptor Pharmacology Varun Prabhu, PhD, Oncoceutics
    7:30 – 9:30 PM Ballroom Lawn Single agent ONC201 in previously treated, progressive adult H3 K27M-mutant glioma Isabel Arrillaga-Romany, MD, PhD, MGH
    7:30 – 9:30 PM Ballroom Lawn Role of ONC206 in regulating medulloblastoma tumor progression Anshu Malhotra, PhD, Emory University
    7:38 – 7:42 PM Wildflower B Receptor pharmacology of ONC201: The first bitopic DRD2 antagonist for clinical neuro-oncology Josh Allen, PhD, Oncoceutics

    Saturday 11/23
    7:15 – 8:30 AM Grand Canyon 8-13 H3K27M glioma and ONC201 (SNO-EANO Joint session) Isabel Arrillaga-Romany, MD, PhD, MGH
    3:45 – 3:55 PM Grand Canyon 1-6 Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma Carl Koschmann, MD, Michigan Medicine
    4:40 – 4:45 PM Grand Canyon 1-6 Phase I clinical trial of ONC201 in pediatric H3 K27M-mutant glioma or newly diagnosed DIPG Sharon Gardner, MD, NYU Langone Health
    5:00 – 7:00 PM Ballroom Lawn Preclinical combination of ONC201 with radiotherapy or Temozolomide in GBM, DIPG and ATRT cell lines results in dopamine receptor antagonism, ATF4 induction and cell death Lanlan Zhou, MD, PhD, Brown University
    5:00 – 7:00 PM Ballroom Lawn Metabolic rewiring by ONC201/TIC10 and 2-Deoxyglucose has synergistic anti-glioblastoma activity Josh Allen, PhD, Oncoceutics
    5:00 – 7:00 PM Ballroom Lawn PDTM-25 Study of ONC201 in pre-clinical models of DIPG Wafik Zaky, MD, MD Anderson
    5:00 – 7:00 PM Ballroom Lawn IND-enabling Characterization of ONC206 as the Next Bitopic DRD2 antagonist for Neuro-oncology Varun Prabhu, PhD, Oncoceutics

    About Oncoceutics

    Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist, the first one that exhibits a highly specific bi-topic binding to the receptor. The company is supported by grants from the NCI, FDA, The Musella Foundation, and a series of private and public partnerships. Visit Oncoceutics or contact Press@oncoceutics.com for more information.

    Visit Oncoceutics or contact press@oncoceutics.com for more information.